Shorter Duration Chemotherapy Possible for Early Stage Colon Cancer

Many colon cancer patients can cut their chemotherapy regimenin half improving their quality of life and reducing their chances of having debilitating side effects according to the results of a major study released at the American Society of Clinical Onco [...]

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation

The US Food and Drug Administration granted regular approvals to Tafinlar dabrafenib and Mekinist trametinib administered in combination for patients with metastatic non-small cell lung cancer NSCLC with BRAF V600E mutation as detected by an FDA-approved [...]

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor durvalumabMEDI4736 with chemotherapy as preoperative treatment for early stage triple negati [...]

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia

According to early clinical trial results published in the journal Blood some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy AML is the most lethal of the blood cancers whic [...]

FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma

The US Food and Drug Administration FDA has granted Fast Track designation to CB-839 in combination with afinitor everolimus for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy CB-839 is a [...]

With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma

Keytruda pembrolizumab continues to outperform Yervoy ipilimumab as initial treatment of patients with advanced melanoma Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology ASCO report [...]

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia

In 2002 the FDA approved the drug Gleevec imatinib as a first-line therapy for adults with chronic myeloid leukemia CML caused by the fusion gene BCR-ABL known as the Philadelphia chromosome The approval dramatically extended the lives of patients with th [...]

Alecensa Superior to Xalkori in Treatment of Lung Cancer

Alecensa alectinib halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori crizotinib with fewer side effects according to trial results presented at the 2017 American Society of Clinical Oncology annual meeting [...]

Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer

The results from the I-SPY 2 TRIAL investigating Keyytrudapembrolizumab in combination with standard therapy as a pre-operative neoadjuvant treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical O [...]

FDA Expands use of Zykadia® in First-Line ALK-Positive Non-Small Cell Lung Cancer

The US Food and Drug Administration FDA approved the expanded use of Zykadiaceritinib to include the first-line treatment of patients with metastatic non-small cell lung cancer NSCLC whose cancers are anaplastic lymphoma kinase ALK-positive as detected by [...]